Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BC 001 - Sichuan Luzhou Buchang Biopharmaceutical

Next Previous
Search
Drug Profile

BC 001 - Sichuan Luzhou Buchang Biopharmaceutical

Alternative Names: BC-001 - Sichuan Luzhou Buchang Biopharmaceutical

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Luzhou Buchang Biopharmaceutical
  • Class Antineoplastics; Immunoglobulins; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal cancer

Most Recent Events

  • 28 Mar 2025 Efficacy, adverse event and pharmacokinetic data from a phase I trial in Gastrointestinal cancer released by Sichuan Luzhou Buchang Biopharmaceutical(https://pubmed.ncbi.nlm.nih.gov/39562838/#:~:text=Phase%20I%20study%20of%20BC001,2%2C%20in%20advanced%20solid%20tumors)
  • 28 Mar 2025 Pharmacodynamics data from a preclinical trial in cancer released by Sichuan Luzhou Buchang Biopharmaceutical (
    https://pubmed.ncbi.nlm.nih.gov/25269419/#:~:text=Here%20we%20show%20that%20BC001,in%20vitro%20and%20in%20vivo)
  • 28 Feb 2025 Phase-I clinical trials in Gastrointestinal cancer (Late-stage disease, Metastatic disease, Combination therapy) in China (IV) (NCT06773312)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top